How to Apply to Shionogi

10 min read Last updated April 20, 2026 3 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Shionogi is a mid-sized, research-focused Japanese pharma headquartered in Osaka with roughly 5,300 employees, materially smaller than Takeda, Astellas, or Daiichi Sankyo.
  • The company's economics still rest on the legacy Crestor licensing relationship with AstraZeneca, the ViiV HIV joint venture with GSK and Pfizer, and the Xocova COVID antiviral franchise.
  • Crestor's U.S. patent expired in 2016, and the resulting royalty decline is the central strategic backdrop for everything Shionogi has done in the last decade.
  • Xocova (ensitrelvir) is the company's most visible growth bet, with a 2024-2025 global expansion push including a U.S. NDA filing, but its long-term franchise value is genuinely uncertain.
  • Hiring is split into shinsotsu (new graduate) and chuto saiyo (mid-career) tracks for Japan, with separate global postings for U.S. and EU roles through Shionogi Inc. and Shionogi B.V.
  • HQ-based roles expect Japanese rirekisho and shokumukeirekisho, business-level Japanese, and MR certification for field commercial roles.
  • Interviews follow standard Japanese pharma formality with an Osaka inflection: more direct, more personable, but still hierarchical and tenure-oriented.
  • New-graduate compensation typically lands in the roughly 6 to 10 million JPY range over the first few years including bonus, with mid-career bands tied tightly to age and grade.
  • Candidates who treat Shionogi as interchangeable with larger Japanese pharma peers tend to lose offers to those competitors; specificity about Shionogi's chemistry, infectious disease, and ViiV story matters.

About Shionogi

Shionogi & Co., Ltd. (TSE: 4507) is a mid-sized Japanese pharmaceutical company headquartered in Doshomachi, Osaka, the historic apothecary district where it was founded in 1878 by Gisaburo Shiono as a traditional Japanese and Western medicine wholesaler. From those Meiji-era roots, Shionogi grew into one of Japan's most research-driven pharmaceutical firms, known for a comparatively narrow but scientifically credible portfolio rather than the sprawling product catalogs of larger Japanese peers like Takeda, Astellas, or Daiichi Sankyo. With approximately 5,300 employees worldwide, Shionogi remains meaningfully smaller than its top-three Japanese pharmaceutical peers, and that scale is part of its self-image: a focused, science-led house with an Osaka identity rather than a Tokyo conglomerate. The company's defining historical product is rosuvastatin, the cholesterol-lowering statin Shionogi discovered and licensed globally to AstraZeneca, which marketed it as Crestor and turned it into one of the best-selling cardiovascular drugs of the 2000s. Royalty income from Crestor effectively funded a generation of Shionogi R&D, but the U.S. patent expired in 2016 and the global generic erosion that followed has been the single most important strategic backdrop for the company ever since. Shionogi's response has centered on infectious disease, an area where it has long-standing chemistry expertise. In partnership with GlaxoSmithKline and Pfizer, Shionogi co-owns ViiV Healthcare, the HIV-focused joint venture that markets dolutegravir-based regimens (Tivicay, Triumeq) and the long-acting injectable cabotegravir (Vocabria/Apretude). ViiV royalties and equity income are now a major Shionogi profit driver and partly offset the post-Crestor revenue decline. The company's most visible recent program is Xocova (ensitrelvir fumaric acid), an oral 3CL protease inhibitor for COVID-19 that received emergency regulatory approval in Japan in November 2022 and has been the focus of an aggressive 2024-2025 global expansion push, including a U.S. New Drug Application filing for post-exposure prophylaxis and ongoing Phase III work in additional indications. Whether Xocova becomes a durable franchise or a niche product remains genuinely uncertain: it competes with Pfizer's Paxlovid, faces a COVID market that has normalized into a seasonal respiratory category, and depends heavily on regulatory acceptance outside Japan. Beyond COVID and HIV, Shionogi markets Symbicort in Japan under license from AstraZeneca, sells the antibiotic cefiderocol (Fetroja) for multi-drug-resistant Gram-negative infections, and has earlier-stage programs in pain, central nervous system disorders, and infectious disease. Leadership has been in transition: Isao Teshirogi, who served as President and CEO for more than a decade and personally championed the Xocova program, handed operational leadership to a new generation, with Takuko Sawada (long-serving director and Senior Executive Officer) playing a more prominent role in 2024 and beyond. Headquarters remain firmly in Osaka, with major R&D in Toyonaka, manufacturing in Settsu and Kanegasaki, and overseas offices in London, New Jersey, and Shanghai. Honest framing matters: Shionogi is a respected, scientifically credible mid-cap, but it is not a global top-twenty pharma, the post-Crestor revenue base is structurally smaller than peers, and Japanese pharmaceutical industry consolidation (driven by aging demographics, NHI price cuts, and the costs of global development) is an ongoing pressure that no mid-sized Japanese pharma can ignore.

Application Process

  1. 1
    Identify the right track

    Identify the right track. Shionogi's Japanese hiring is split into shinsotsu (new graduate) recruiting through the corporate site at shionogi.com/jp/ja/recruit and chuto saiyo (mid-career) postings at shionogi.com/jp/ja/recruit/career. Global roles are listed separately under shionogi.com/global/en/careers and feed into local subsidiary HR (Shionogi Inc. in Florham Park, NJ; Shionogi B.V. in London).

  2. 2
    Submit through the official site, not aggregators

    Submit through the official site, not aggregators. Shionogi posts directly on its own corporate careers pages and (for some Japanese mid-career roles) on Bizreach, doda, and JAC Recruitment. Verify the ATS by navigating from shionogi.com itself; do not rely on third-party reposts that may be stale or inaccurate.

  3. 3
    Prepare Japanese-format documents for HQ roles

    Prepare Japanese-format documents for HQ roles. New-graduate and most Osaka-based mid-career applications expect a Japanese-style rirekisho (resume) and shokumukeirekisho (work history), often with a face photograph and handwritten or typed Japanese. Foreign applicants for global functions should still attach an English CV but expect a Japanese version to be requested.

  4. 4
    Expect SPI or equivalent aptitude testing for new graduates

    Expect SPI or equivalent aptitude testing for new graduates. Japanese pharmaceutical shinsotsu hiring typically includes the SPI3 or TG-WEB aptitude test (numerical, verbal, logic, and personality components). MR (medical representative) candidates may also face industry-specific written assessments.

  5. 5
    Plan for multiple interview rounds

    Plan for multiple interview rounds. New-graduate recruiting commonly runs three to four rounds: HR screen, manager interview, senior leadership panel, and a final executive interview. Mid-career and global roles typically run two to three rounds with a mix of hiring manager, technical peers, and an HR business partner.

  6. 6
    Confirm work authorization and language expectations early

    Confirm work authorization and language expectations early. Japan-based roles generally require business-level Japanese (JLPT N1 or near-native) unless the position is explicitly designated as global or English-capable. U.S. and EU roles follow local labor and visa norms, with Shionogi Inc. and Shionogi B.V. handling sponsorship case by case.

  7. 7
    Independently verify the ATS

    Independently verify the ATS. Shionogi's career system is a corporate-branded portal layered over its HR backend rather than a single named global ATS like Workday or Taleo, and the underlying provider can vary by region and by year. Treat the ATS field below as illustrative only and confirm what you actually see in the application URL when you apply.

Resume Tips for Shionogi

recommended

Submit a Japanese rirekisho and shokumukeirekisho for any HQ-based role

Submit a Japanese rirekisho and shokumukeirekisho for any HQ-based role. Standard JIS-format rirekisho with photograph, plus a detailed shokumukeirekisho organized chronologically by company and role, is the baseline expectation in Osaka and Tokyo offices.

recommended

Quantify pharmacology, chemistry, and clinical experience

Quantify pharmacology, chemistry, and clinical experience. Shionogi is a chemistry-led pharma; medicinal chemistry, infectious disease biology, virology, formulation science, and clinical pharmacology backgrounds are read closely. Cite publications, patents, and conference presentations explicitly.

recommended

Emphasize MR (medical representative) credentials if applying to commercial role

Emphasize MR (medical representative) credentials if applying to commercial roles. Japanese MR certification (MR Nintei Shiken) issued by the MR Education and Accreditation Center is effectively required for field-based promotional roles and should be listed prominently with your certification number and date.

recommended

Lead with ViiV, GSK, or other multinational collaboration experience for global

Lead with ViiV, GSK, or other multinational collaboration experience for global roles. Shionogi's identity in HIV runs through ViiV Healthcare, and any prior work with GSK, Pfizer, or large multinational pharma is directly relevant for global development, alliance management, and medical affairs positions.

recommended

Use English for global functions and bilingual presentation when in doubt

Use English for global functions and bilingual presentation when in doubt. Global development, regulatory affairs interfacing with FDA or EMA, and overseas commercial roles default to English. A clean English CV with a Japanese summary section signals readiness for cross-border collaboration.

recommended

Show evidence of long tenure and stability for HQ roles

Show evidence of long tenure and stability for HQ roles. Japanese pharmaceutical employers, including Shionogi, weight long, coherent career arcs heavily. Frequent job changes, especially within five years, should be explained directly in the shokumukeirekisho rather than left ambiguous.

recommended

Highlight infectious disease, antiviral, or anti-infective expertise

Highlight infectious disease, antiviral, or anti-infective expertise. Given Xocova, cefiderocol, and the HIV franchise, antiviral chemistry, infectious disease clinical development, AMR (antimicrobial resistance) policy, and vaccine adjacent work are differentiated qualifications.

recommended

Be explicit about Japanese language ability

Be explicit about Japanese language ability. State JLPT level, years lived or worked in Japan, and any Japanese-medium degrees. Vague phrases like 'conversational Japanese' are read as N3 or below by Japanese HR and will hurt rather than help.

ATS System: Shionogi corporate careers portal (Japan and global), with regional HR systems for Shionogi Inc. (U.S.) and Shionogi B.V. (Europe)

Interview Culture

Shionogi interviews carry the formality typical of established Japanese pharmaceutical companies, with the additional flavor of Osaka business culture.

Expect the standard Japanese interview choreography: punctual arrival (ten minutes early, not earlier), conservative dark business suit, restrained greeting at the door, exchange of meishi (business cards) with both hands and a brief moment of attentive reading before placing cards on the table, seating only when invited, and a measured, mid-volume speaking pace. Interviewers will typically be a mix of HR, the hiring manager, and at later rounds a senior executive or board-level officer, and the questioning style tends toward depth on a small number of topics rather than rapid-fire breadth. For research and clinical roles, expect a substantive technical interview that probes mechanism-level understanding and asks you to defend specific experimental or trial design choices; superficial answers are read as a lack of seriousness. Osaka business culture is meaningfully different from Tokyo: it is more direct, more comfortable with humor and personality, and more willing to discuss commercial reality than Tokyo's more reserved norm, but the underlying expectation of group harmony, indirect disagreement, and respect for senior colleagues is fully present. Shionogi's identity as a smaller, research-focused house also shapes the conversation. Interviewers are likely to ask why you chose Shionogi specifically over Takeda, Astellas, or Daiichi Sankyo, and a credible answer needs to engage with the company's historical Crestor science, its infectious disease focus, the ViiV partnership, and the Xocova program rather than generic statements about wanting to work at a Japanese pharma. Expect at least one question about your understanding of NHI drug pricing pressure, generic erosion, and the strategic rationale for Shionogi's overseas push; candidates who treat the company as a domestic Japanese employer rather than a globalizing mid-cap tend to fall behind. Final-round interviews with senior executives will often shift away from technical depth and toward character, longevity, and fit, with questions about how you would approach a multi-decade career, your relationship with previous managers, and your willingness to relocate within Japan or to overseas offices. Compensation discussion is typically deferred to HR after the technical rounds and is rarely negotiated aggressively; Japanese pharma compensation bands are relatively rigid and tied to age, tenure, and grade.

What Shionogi Looks For

  • Genuine scientific depth in chemistry, infectious disease, virology, or clinical pharmacology rather than generalist credentials, reflecting Shionogi's research-led identity.
  • Long-term commitment and willingness to build a career inside one company, consistent with Japanese pharmaceutical norms around tenure and internal mobility.
  • Working Japanese for HQ roles (JLPT N1 or near-native preferred) and credible English for global development, regulatory, and alliance roles.
  • Demonstrated ability to operate inside structured, hierarchical decision-making without losing technical conviction, particularly for mid-career hires from multinational pharma.
  • MR certification and field-sales discipline for commercial roles, with evidence of physician-facing relationship building and adherence to Japanese promotional code.
  • Awareness of the post-Crestor revenue context, the Xocova growth thesis, and the ViiV partnership as economic pillars, signaling that you understand what Shionogi actually is.
  • Cultural fit with Osaka business style: directness leavened by warmth, comfort with personality, and respect for the company's 1878 lineage.
  • Integrity and risk discipline, especially for development, regulatory, and pharmacovigilance roles, where Japanese regulators (PMDA) and global authorities (FDA, EMA) all impose high audit expectations.

Frequently Asked Questions

What is the typical starting salary for a new graduate at Shionogi?
Japanese pharmaceutical shinsotsu compensation for research and development positions typically begins around 250,000 to 280,000 JPY per month for a master's degree holder, with summer and winter bonuses that bring the first-year total cash to roughly 5 to 6 million JPY. By the third to fifth year, total compensation commonly reaches 6 to 10 million JPY depending on role, location allowances, and bonus performance. PhD entrants and MR-track hires can land at the upper end of that range. Shionogi's published recruitment pages and standard Japanese industry surveys (Toyo Keizai, Nikkei) are the most reliable references.
Do I need to speak Japanese to work at Shionogi?
For any role based in Osaka or elsewhere in Japan, business-level Japanese is effectively required, with JLPT N1 or near-native proficiency expected for research, clinical, regulatory, and commercial roles. A small number of global development, alliance management, and overseas-facing positions operate primarily in English, but they are still part of a Japanese-headquartered organization where senior decisions are often discussed in Japanese. Shionogi Inc. (U.S.) and Shionogi B.V. (Europe) operate in English, and roles based at those subsidiaries do not require Japanese.
What is the MR (medical representative) track and is it different from other commercial roles?
MR is the Japanese pharmaceutical industry's regulated field-sales role, governed by the MR Education and Accreditation Center and requiring the MR Nintei Shiken certification. MRs visit physicians, hospitals, and pharmacies to provide regulated drug information under Japan's promotional code. The MR career path at Shionogi is largely separate from marketing, market access, or medical affairs roles, has its own training program, and often involves nationwide rotation. Mid-career hires from outside the industry can enter, but certification within the first year or two is expected.
Why do candidates often pick Takeda, Astellas, or Daiichi Sankyo over Shionogi?
The honest answer is scale and global reach. Takeda is Japan's largest pharma with a Boston-anchored global footprint, Astellas has a stronger U.S. oncology and urology presence, and Daiichi Sankyo's enhertu-led oncology franchise has driven outsized recent growth. Each offers larger compensation bands at senior levels, broader international rotation, and more cushion against single-product risk. Shionogi competes on focus, scientific identity, Osaka culture, and the chance to work close to the chemistry rather than inside a larger bureaucracy. Candidates who value depth over scale often choose Shionogi; those optimizing for global mobility and brand often choose the top three.
How exposed is Shionogi to the post-Crestor revenue decline?
Materially exposed, and this should inform any candidate's evaluation. Crestor royalties from AstraZeneca were a defining contributor to Shionogi's profitability through the 2010s, and U.S. patent expiry in 2016 plus subsequent global generic erosion permanently reset the company's revenue base downward. Management has used the period since to build the ViiV equity income stream, expand cefiderocol, and bet on Xocova. The result is a leaner, more focused company, but also one where any single product setback is felt more than at larger peers. This is not a reason to avoid Shionogi, but it is a reason to ask hard questions in interviews.
What is the Xocova growth thesis and how realistic is it?
Xocova (ensitrelvir) is an oral 3CL protease inhibitor approved under emergency regulatory pathways in Japan in November 2022 for COVID-19. Shionogi's 2024-2025 strategy has centered on global expansion: a U.S. New Drug Application targeting post-exposure prophylaxis, ongoing Phase III work in additional indications, and licensing discussions outside Japan. The thesis depends on (1) FDA acceptance, (2) differentiation from Pfizer's Paxlovid, and (3) sustained COVID demand as the disease becomes a normalized seasonal respiratory illness. Each of those is contested. A reasonable candidate posture is to take the program seriously without treating its commercial outcome as settled.
What is the ViiV Healthcare relationship and why does it matter for hiring?
ViiV Healthcare is a London-based HIV-focused company majority-owned by GSK with Pfizer and Shionogi as minority shareholders. Shionogi originated the dolutegravir chemistry that anchors ViiV's franchise (Tivicay, Triumeq, Dovato) and contributes to the long-acting cabotegravir injectable (Vocabria, Apretude). For Shionogi employees, ViiV is both a major source of equity income and a working partnership: alliance management, joint development, and co-commercialization roles routinely interface with ViiV staff in London and Research Triangle Park. Any GSK or ViiV experience is directly relevant when applying to Shionogi global roles.
What is Shionogi's culture like compared with Tokyo-based pharmas?
Shionogi is unmistakably an Osaka company, and Osaka business culture differs from Tokyo in real ways: more direct conversation, more comfort with humor and personality, more willingness to discuss commercial and competitive reality openly, and somewhat less of the extreme indirectness that characterizes Tokyo finance and consulting culture. Underneath that, the standard Japanese pharmaceutical norms are fully present: hierarchy, tenure, group decision making, slow promotion, and very high expectations of long-term commitment. Foreign hires often find Shionogi more approachable than Tokyo peers but should not mistake openness for informality.
Does Shionogi sponsor work visas for foreign hires in Japan?
Yes for genuinely needed roles, particularly in global development, regulatory affairs interfacing with overseas authorities, and certain research positions where the company actively seeks international expertise. Sponsorship is handled through Japan's standard Engineer/Specialist in Humanities/International Services or Highly Skilled Professional visa categories. For most HQ-based commercial and MR roles, however, Japanese language and existing work authorization are effectively prerequisites, and visa sponsorship is uncommon. The most reliable path for non-Japanese candidates is through Shionogi Inc. (NJ) or Shionogi B.V. (London), which hire under local norms.
What does the leadership transition from Isao Teshirogi mean for hiring?
Isao Teshirogi served as President and CEO for more than a decade and was the public face of Shionogi's infectious disease pivot, including the Xocova program. The 2024 leadership evolution, with figures such as Takuko Sawada (long-serving director and Senior Executive Officer) taking on more prominent operational roles, is best read as a planned generational handoff rather than a strategic break. For candidates, it means the strategic picture (infectious disease focus, ViiV reliance, post-Crestor repositioning) is broadly stable, but specific organizational priorities and reporting lines may continue to shift through 2025 and 2026. Confirm current org structure during interviews.

Open Positions

Shionogi currently has 3 open positions.

Check Your Resume Before Applying → View 3 open positions at Shionogi

Related Resources

Similar Companies

Sources

  1. Shionogi & Co., Ltd. corporate website —
  2. Shionogi global careers —
  3. Shionogi Japan recruitment site (新卒・キャリア採用) —
  4. Shionogi Annual Report and Integrated Report (investor relations) —
  5. ViiV Healthcare ownership and Shionogi partnership —
  6. Xocova (ensitrelvir) Japanese emergency approval (PMDA) —
  7. AstraZeneca Crestor (rosuvastatin) licensing background —
  8. MR Education and Accreditation Center of Japan (MR認定センター) —